Tiziana announces strategic initiative with takanawa japan k.k., pharma team, to identify a partner in japan and other asian countries for further clinical development of milciclib in patients with advanced hepatocellular carcinoma.

New york and london, may 05, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa / lse: tils) (“tiziana” or the “company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that it has executed an agreement with takanawa japan k.k, pharma team, (takanawa) for a strategic business development plan to identify a clinical partner in japan and other asian countries for further clinical development of milciclib for treatment in advanced hepatocellular carcinoma (hcc) patients. hcc is the most common type of liver cancer and affects approximately 200,000 people per year.
TLSA Ratings Summary
TLSA Quant Ranking